Amgen’s oncology portfolio focuses on targeted therapies and immunotherapies for hematologic malignancies and solid tumors, featuring key products like BLINCYTO® (blinatumomab) for leukemia, LUMAKRAS® (sotorasib) for KRAS G12C-mutated cancers, and IMDELLTRA® (tarlatamab) for small cell lung cancer. The portfolio also includes supportive care treatments and biosimilars (e.g., MVASI®) to address various cancer treatment needs.

Key Amgen Oncology Products and Pipeline (as of 2025/2026):
BLINCYTO® (blinatumomab): A BiTE® (bispecific T-cell engager) molecule used for relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
LUMAKRAS® (sotorasib): A first-in-class small molecule inhibitor targeting the KRAS G12C mutation, indicated for NSCLC and investigated for colorectal cancer.
IMDELLTRA® (tarlatamab-dlle): A DLL3-targeted BiTE molecule for extensive-stage small cell lung cancer (SCLC).
KYPROLIS® (carfilzomib): A proteasome inhibitor for the treatment of relapsed or refractory multiple myeloma.
Vectibix® (panitumumab): A monoclonal antibody targeting EGFR for metastatic colorectal cancer.
XGEVA® (denosumab): RANKL inhibitor used to prevent skeletal-related events in bone metastases from solid tumors.
Nplate® (romiplostim): Thrombopoietin receptor agonist for chronic immune thrombocytopenia.

Biosimilars: A portfolio of 11 approved or in-development biosimilars, including MVASI® (bevacizumab-awwb) and KANJINTI® (trastuzumab-anns).
Amgen is actively developing novel, targeted therapies, including additional BiTE molecules and small molecules for hard-to-treat cancers.